ID   SW872
AC   CVCL_1730
SY   SW-872; SW 872
DR   BTO; BTO:0003743
DR   CLO; CLO_0009201
DR   EFO; EFO_0002373
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-92
DR   BCRC; 60432
DR   BioSample; SAMN03472763
DR   CCLE; SW872_SOFT_TISSUE
DR   Cell_Model_Passport; SIDM01159
DR   ChEMBL-Cells; CHEMBL3308837
DR   ChEMBL-Targets; CHEMBL2366302
DR   CLS; 300405/p537_SW-872
DR   Cosmic; 684521
DR   Cosmic; 909756
DR   Cosmic; 923383
DR   Cosmic; 2009544
DR   Cosmic; 2307722
DR   Cosmic; 2560246
DR   Cosmic-CLP; 909756
DR   GDSC; 909756
DR   GEO; GSM185156
DR   GEO; GSM185157
DR   GEO; GSM482514
DR   GEO; GSM1543668
DR   GEO; GSM1543669
DR   GEO; GSM1670514
DR   IARC_TP53; 24518
DR   IGRhCellID; SW872
DR   IZSLER; BS TCL 119
DR   LINCS_LDP; LCL-1459
DR   Lonza; 88
DR   NCBI_Iran; C638
DR   Wikidata; Q54971215
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=16888811;
RX   PubMed=17431109;
RX   PubMed=20215515;
RX   PubMed=22911243;
RX   PubMed=24726063;
RX   PubMed=24758355;
RX   PubMed=27397505;
RX   PubMed=28196595;
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Scott and White Clinic; Temple; USA.
CC   Doubling time: 24 hours (PubMed=16888811).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Heterozygous for BRAF p.Val600Glu (c.1799T>A) (ATCC).
CC   Sequence variation: Homozygous for CDKN2A p.Arg80Ter (c.237_238delinsTT) (ATCC).
CC   Sequence variation: Homozygous for PTEN deletion (ATCC).
CC   Sequence variation: TP53 p.Ile251Asn (c.752T>A) (PubMed=16888811).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Misspelling: SW672; In PubMed=17431109.
ST   Source(s): ATCC; CLS; Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 9,12
ST   D18S51: 12,16
ST   D21S11: 27,31.2
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   D8S1179: 12,15
ST   FGA: 21.2,23
ST   Penta D: 9,10
ST   Penta E: 5,10
ST   TH01: 8,10
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C3194; Liposarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   36Y
CA   Cancer cell line
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=16888811; DOI=10.1002/jcb.21073;
RA   Moneo V., Serelde B.G., Fominaya J., Leal J.F.M., Blanco-Aparicio C.,
RA   Romero L., Sanchez-Beato M., Cigudosa J.C., Tercero J.C., Piris M.A.,
RA   Jimeno J., Carnero A.;
RT   "Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged
RT   sarcoma cell lines correlates with mutated p53.";
RL   J. Cell. Biochem. 100:339-348(2007).
//
RX   PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729;
RA   Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C.,
RA   Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J., Carnero A.;
RT   "Levels of p27(kip1) determine Aplidin sensitivity.";
RL   Mol. Cancer Ther. 6:1310-1316(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22911243; DOI=10.1155/2012/148614;
RA   Stratford E.W., Castro R., Daffinrud J., Skarn M., Lauvrak S.,
RA   Munthe E., Myklebost O.;
RT   "Characterization of liposarcoma cell lines for preclinical and
RT   biological studies.";
RL   Sarcoma 2012:148614-148614(2012).
//
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33-33(2014).
//
RX   PubMed=24758355; DOI=10.1186/1471-2407-14-281;
RA   Moneo V., Serelde B.G., Blanco-Aparicio C., Diaz-Uriarte R.,
RA   Aviles P., Santamaria G., Tercero J.C., Cuevas C., Carnero A.;
RT   "Levels of active tyrosine kinase receptor determine the tumor
RT   response to Zalypsis.";
RL   BMC Cancer 14:281-281(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//